IntegraGen SA (ENXTPA: ALINT)
Health Care · Biotechnology · FR
€0.04
-40.86% today · -54.8% 1Y
IntegraGen SA (ENXTPA: ALINT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $519.56K and employs 37 people.
Over the last twelve months the share price has lost 54.8%, trading between 0.07 and 0.36.
Tweenvest scores IntegraGen SA across four factors: quality 58/100, value 59/100, growth 0/100. Its strongest factor is value.
ALINT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $519.56K
- Revenue (TTM)
- $5.90M
- P/E
- —
- EPS
- -0.40
- Dividend yield
- —
- Beta (5Y)
- 0.52
- 52-week high
- €0.36
- 52-week low
- €0.07
- Avg volume (3M)
- —
- Shares outstanding
- 6.59M
- Employees
- 37
- Next earnings
- —
About IntegraGen SA
IntegraGen S.A. provides advanced human genome analysis services to academic researchers and life science businesses across France. Their comprehensive genomic offerings include transcriptomics, epigenomics, DNA sequencing, next-generation sequencing (NGS) specifically for cancer research, and SNP genotyping. The company also delivers clinical research solutions, such as clinical-grade sequencing and pharmacogenomic studies, in addition to supporting fundamental human genetic investigations. For agricultural applications, IntegraGen offers agrigenomic services covering crop and livestock genotyping, as well as high-throughput sequencing for these domains. Their microbial genomics division conducts whole-genome microbial sequencing and transcriptomics. IntegraGen further develops a suite of sophisticated bioinformatics tools: MERCURY is an online platform for oncology, designed to transform raw high-throughput sequencing data into molecular reports for translational and clinical research. SIRIUS, a cloud-based software, empowers researchers to analyze whole genome, whole exome, and gene panel sequencing information. Galileo is another cloud application that enables dynamic exploration of RNA-Seq expression data. Finally, GeCo, their genomic consulting service, provides researchers access to expert biostatisticians and bioanalysts. Founded in 2000 and headquartered in Évry, France, IntegraGen S.A. is a subsidiary of OncoDNA SA.
- ISIN
- FR0010908723
- Founded
- 2000
- Listed since
- Jun 18, 2010
- Exchange
- Euronext Paris
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| ZyVersa Therapeutics, Inc.OTCPK: ZVSA | $647.67K | $0.08 | -19.19% |
| Biodexa Pharmaceuticals PlcNasdaqCM: BDRX | $637.92K | $0.62 | -8.30% |
| Entheon Biomedical Corp.CNSX: ENBI.X | $586.97K | CA$0.06 | +20.00% |
| Ludwig Enterprises, Inc.OTCPK: LUDG | $585.08K | $0.00 | -65.00% |
| NovelStem International Corp.OTCPK: NSTM | $468.66K | $0.01 | -7.41% |
| Sorrento Therapeutics, Inc.OTCPK: SRNE | $434.97K | $0.00 | +166.67% |
| Vaxil Bio Ltd.TSXV: VXL | $405.24K | CA$0.15 | -3.33% |
| Asia Green Biotechnology Corp.CNSX: ASIA | $400.48K | CA$— | — |
Figures last refreshed Oct 4, 2026.